Wave Life Sciences reports positive target engagement data for WVE-007 in obesity; Activin E reductions up to 85%

Wave Life Sciences Ltd.

WVE-007 achieved Activin E reductions of 85% (400mg), 75% (240mg), 56% (75mg) at one month, all highly significant (p<0.0001).
75mg cohort showed durable reduction through 6 months, supporting once or twice yearly dosing.
WVE-007 safe and well tolerated; independent data monitoring committee supported dose expansion and escalation.
Multiple clinical data updates including body composition and weight expected starting 4Q2025.
Announced WVE-008 RNA editing candidate for PNPLA3 liver disease; CTA filing anticipated in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.